InvestSMART

Amplia Therapeutics Limited (ASX:ATX)

ALERT: Price-sensitive ASX Announcement for ATX
Current share price for ATX : $0.135 -0.003 (-1.82%)+
Announcement
Release
29 May 2026 1:37PM
Price at Release
$0.138
Full Release
download
Summary
Amplia Therapeutics Limited's financial report for the year ending 31 March 2026, highlights a post-tax loss of $7,707,152, driven by increased research and development expenses, notably for the ACCENT trial involving narmafotinib. Despite this loss, the company raised $27.65 million in capital and had cash and cash equivalents of $27,854,032. The report notes no borrowings or dividend payments, and the issuance of 513,071,629 shares. The company holds a key intangible asset in the form of worldwide licenses for AMP945 and AMP886, which are crucial for its continued focus on drug development. The ACCENT clinical trial remains central to the company's efforts, reflecting ongoing investment in its lead drug candidates.
Key Points
  • The Group's loss after tax for the year ended 31 March 2026 was $7,707,152.
  • Research and development expenses increased to $9,079,230.
  • The Group raised $27.65 million of capital.
  • Cash and cash equivalents held were $27,854,032.
  • No dividends were paid or declared.
  • The number of shares on issue at 31 March 2026 was 513,071,629.
  • The Group's key intangible asset is the worldwide license for AMP945 and AMP886.
  • The ACCENT clinical trial is progressing with lead candidate narmafotinib.
  • No borrowings were held as of 31 March 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.